Anti-CD20 therapy and pauci-immune crescentic glomerulonephritis

J Formos Med Assoc. 2017 Apr;116(4):215-216. doi: 10.1016/j.jfma.2015.12.003. Epub 2016 Jan 16.

Authors

Kai-Hsiang Shu¹, Wen-Chih Chiang², Yen-Ling Chiu³

Affiliations

¹ Renal Division, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
² Renal Division, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
³ Renal Division, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan; Program in Biomedical Informatics, Yuan Ze University, Taoyuan City, Taiwan. Electronic address: [email protected].

PMID: 26786252
DOI: 10.1016/j.jfma.2015.12.003

No abstract available

MeSH terms

Animals
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / drug therapy*
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / immunology
Antibodies, Antineutrophil Cytoplasmic / drug effects
Antibodies, Antineutrophil Cytoplasmic / immunology
Antigens, CD20 / drug effects*
Antigens, CD20 / immunology
Glomerulonephritis / drug therapy*
Glomerulonephritis / immunology
Humans
Immunologic Factors / therapeutic use*
Mice
Rituximab / therapeutic use*

Substances

Antibodies, Antineutrophil Cytoplasmic
Antigens, CD20
Immunologic Factors
Rituximab